Moderna plans to advance its experimental HIV vaccine into clinical testing soon.
A safe and effective HIV vaccine has the potential to significantly disrupt Gilead's business given its HIV therapies generate the lion's share of its total revenue.
Toppling Gilead will be difficult, though, in part because of the challenges in preventing HIV.
